Neurocysticercosis: A Rare Cause of Headache Needing Craniotomy

Overview

Journal Transl Perioper Pain Med

Date 2022 Jul 29

PMID 35903541

Authors

Xiaowei Lu

Ning Miao

Andrew Mannes

Affiliations

Soon will be listed here.

References

Hou Z, Duan Q, Ke Y, An N, Yang H, Liu S . Predictors of Seizure Freedom in Patients Undergoing Surgery for Central Nervous System Infection-Related Epilepsy: A Systematic Review and Meta-Analysis. Front Neurol. 2021; 12:668439. PMC: 8416488. DOI: 10.3389/fneur.2021.668439. View

Del Brutto O, Santibanez R, Noboa C, Aguirre R, Diaz E, Alarcon T . Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. 1992; 42(2):389-92. DOI: 10.1212/wnl.42.2.389. View

Nash T, Pretell E, Lescano A, Bustos J, Gilman R, Gonzalez A . Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 2008; 7(12):1099-105. PMC: 3725597. DOI: 10.1016/S1474-4422(08)70243-6. View

Soriano S, Martyn J . Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance. Clin Pharmacokinet. 2004; 43(2):71-81. DOI: 10.2165/00003088-200443020-00001. View

Suthar R, Sahu J, Ahuja C, Khandelwal N, Sehgal R, Singhi P . A prospective cohort study to assess the frequency and risk factors for calcification in single lesion parenchymal neurocysticercosis. Seizure. 2020; 83:132-138. DOI: 10.1016/j.seizure.2020.10.012. View

Garcia H, Evans C, Nash T, Takayanagui O, White Jr A, Botero D . Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002; 15(4):747-56. PMC: 126865. DOI: 10.1128/CMR.15.4.747-756.2002. View

Verma A, Prasad K, Gupta R, Singh A, Nyati K, Rizwan A . Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis. 2010; 202(8):1219-25. DOI: 10.1086/656395. View

Guzman C, Garcia H . Current Diagnostic Criteria for Neurocysticercosis. Res Rep Trop Med. 2021; 12:197-203. PMC: 8364393. DOI: 10.2147/RRTM.S285393. View

Wilcox S . Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: A historical review. J Crit Care. 2016; 37:149-155. DOI: 10.1016/j.jcrc.2016.09.018. View

10.

DeGiorgio C, Medina M, Duron R, Zee C, Escueta S . Neurocysticercosis. Epilepsy Curr. 2005; 4(3):107-11. PMC: 1176337. DOI: 10.1111/j.1535-7597.2004.43008.x. View

11.

Serpa J, White Jr A . Neurocysticercosis in the United States. Pathog Glob Health. 2012; 106(5):256-60. PMC: 4005108. DOI: 10.1179/2047773212Y.0000000028. View

12.

Schmid M, Perosa S, Reyes-Garcia S, Odreman M, Zetehaku A, Figueiredo N . Neurocysticercosis and pharmacoresistant epilepsy: possible role of calcified lesions in epileptogenesis. Epileptic Disord. 2020; 22(4):506-510. DOI: 10.1684/epd.2020.1188. View

13.

Prodjinotho U, Lema J, Lacorcia M, Schmidt V, Vejzagic N, Sikasunge C . Host immune responses during Taenia solium Neurocysticercosis infection and treatment. PLoS Negl Trop Dis. 2020; 14(4):e0008005. PMC: 7162612. DOI: 10.1371/journal.pntd.0008005. View

14.

Coyle C . Neurocysticerosis: An Individualized Approach. Infect Dis Clin North Am. 2019; 33(1):153-168. DOI: 10.1016/j.idc.2018.10.007. View